Stock Price Prediction

DRRX stock is currently trading at $0.83, with a bullish price target of $6.75 based on analyst consensus. The optimism stems from promising Phase 2b trial results for larsucosterol, showing significant mortality reduction in severe alcohol-associated hepatitis patients. However, financing uncertainties for the Phase 3 trial and cash runway risks into Q1 2025 temper the bullish outlook.

DRRX stock, currently priced at $0.765, faces bearish sentiment due to significant financial risks. The company's cash runway is only sufficient until Q1 2025, raising concerns about its ability to fund the upcoming Phase 3 trial for larsucosterol. Despite promising Phase 2b results, the uncertainty around financing and its "going concern" risk weigh heavily on the stock.

The market consensus for DRRX's revenue in the upcoming quarter is projected to be approximately $1000K USD.